Equities Analysts Set Expectations for HIMS Q3 Earnings

Key Points

• KeyCorp analysts predict Hims & Hers Health will report earnings per share of $0.08 for Q3 2025, with a full-year consensus estimate of $0.29.
• The company's stock has recently faced downgrades, with several analysts adjusting their ratings to "hold," indicating a cautious outlook for Hims & Hers Health.
• Institutional investors hold 63.52% of Hims & Hers Health's stock, reflecting strong interest from larger financial entities despite recent insider selling activities.

Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) - Stock analysts at KeyCorp issued their Q3 2025 earnings per share (EPS) estimates for shares of Hims & Hers Health in a note issued to investors on Monday, October 20th. KeyCorp analyst J. Patterson forecasts that the company will post earnings per share of $0.08 for the quarter. KeyCorp has a "Sector Weight" rating on the stock. The consensus estimate for Hims & Hers Health's current full-year earnings is $0.29 per share. KeyCorp also issued estimates for Hims & Hers Health's Q4 2025 earnings at $0.09 EPS, FY2025 earnings at $0.53 EPS, FY2026 earnings at $0.59 EPS and FY2027 earnings at $0.87 EPS.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company's quarterly revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Several other analysts have also recently commented on the company. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Hims & Hers Health in a research report on Tuesday, October 14th. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Truist Financial reduced their price objective on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research note on Monday, August 18th. Finally, Zacks Research lowered Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Stock Down 3.8%

Shares of Hims & Hers Health stock opened at $49.40 on Wednesday. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The business's 50 day simple moving average is $51.07 and its 200-day simple moving average is $49.21. The stock has a market capitalization of $11.17 billion, a price-to-earnings ratio of 61.75, a PEG ratio of 3.50 and a beta of 2.25. Hims & Hers Health has a twelve month low of $18.33 and a twelve month high of $72.98.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently bought and sold shares of the company. Global Retirement Partners LLC boosted its position in Hims & Hers Health by 355.1% during the third quarter. Global Retirement Partners LLC now owns 7,873 shares of the company's stock valued at $447,000 after purchasing an additional 6,143 shares during the last quarter. SteelPeak Wealth LLC acquired a new stake in Hims & Hers Health during the third quarter valued at $255,000. Nicholas Wealth LLC. boosted its position in Hims & Hers Health by 11.7% during the third quarter. Nicholas Wealth LLC. now owns 33,229 shares of the company's stock valued at $1,885,000 after purchasing an additional 3,472 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in Hims & Hers Health by 0.8% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company's stock valued at $1,452,000 after purchasing an additional 200 shares during the last quarter. Finally, Goldstone Financial Group LLC acquired a new stake in Hims & Hers Health during the third quarter valued at $653,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Insiders Place Their Bets

In other news, insider Michael Chi sold 900 shares of the firm's stock in a transaction on Friday, October 10th. The stock was sold at an average price of $58.25, for a total value of $52,425.00. Following the completion of the sale, the insider owned 291,439 shares of the company's stock, valued at $16,976,321.75. This trade represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $506,060.50. Following the sale, the insider directly owned 169,940 shares of the company's stock, valued at approximately $8,581,970. The trade was a 5.57% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,434,306 shares of company stock worth $74,369,240. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.